Matches in Nanopublications for { ?s ?p "[In contrast, SOCE agonists should attenuate mTOR inhibitors-mediated AKT reactivation and consequently potentiate their efficacy in the treatment of the patients with TSC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- assertion description "[In contrast, SOCE agonists should attenuate mTOR inhibitors-mediated AKT reactivation and consequently potentiate their efficacy in the treatment of the patients with TSC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP299092.RAlKCqfXFoTW9Kb1_gJIH8Qw7H2cdDA03Xi_x-d6iflko130_assertion description "[In contrast, SOCE agonists should attenuate mTOR inhibitors-mediated AKT reactivation and consequently potentiate their efficacy in the treatment of the patients with TSC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP299092.RAlKCqfXFoTW9Kb1_gJIH8Qw7H2cdDA03Xi_x-d6iflko130_provenance.
- NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_assertion description "[In contrast, SOCE agonists should attenuate mTOR inhibitors-mediated AKT reactivation and consequently potentiate their efficacy in the treatment of the patients with TSC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_provenance.
- assertion description "[In contrast, SOCE agonists should attenuate mTOR inhibitors-mediated AKT reactivation and consequently potentiate their efficacy in the treatment of the patients with TSC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1024664.RAmt8nbz2ISzy7YVu_k3HUqebKkNgWO4R3aGKb5Fz5Mto130_assertion description "[In contrast, SOCE agonists should attenuate mTOR inhibitors-mediated AKT reactivation and consequently potentiate their efficacy in the treatment of the patients with TSC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1024664.RAmt8nbz2ISzy7YVu_k3HUqebKkNgWO4R3aGKb5Fz5Mto130_provenance.
- NP232284.RALRPNHHFMYA3niQo5zHK6CX0uZd_bSr_AdOcR87tEdnE130_assertion description "[In contrast, SOCE agonists should attenuate mTOR inhibitors-mediated AKT reactivation and consequently potentiate their efficacy in the treatment of the patients with TSC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP232284.RALRPNHHFMYA3niQo5zHK6CX0uZd_bSr_AdOcR87tEdnE130_provenance.
- NP411991.RAG3rtLgLCz9UwsAsEqtdNGMlrIjQOyF8xnw1OMbLK-Ws130_assertion description "[In contrast, SOCE agonists should attenuate mTOR inhibitors-mediated AKT reactivation and consequently potentiate their efficacy in the treatment of the patients with TSC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP411991.RAG3rtLgLCz9UwsAsEqtdNGMlrIjQOyF8xnw1OMbLK-Ws130_provenance.
- NP1024666.RAHAHYTZJZrFHW6l52KG6vXTY5Spgyg3bOz01GrLud_oo130_assertion description "[In contrast, SOCE agonists should attenuate mTOR inhibitors-mediated AKT reactivation and consequently potentiate their efficacy in the treatment of the patients with TSC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1024666.RAHAHYTZJZrFHW6l52KG6vXTY5Spgyg3bOz01GrLud_oo130_provenance.